TITLE

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?

AUTHOR(S)
Schwartz, Stanley; DeFronzo, Ralph A.
PUB. DATE
February 2014
SOURCE
Diabetes Care;Feb2014, Vol. 37 Issue 2, pe42
SOURCE TYPE
Academic Journal
DOC. TYPE
Opinion
ABSTRACT
A response to a commentary on a study that investigated the use of incretin-based therapy for hospitalized patients with hyperglycemia is presented. They assert that the results support their claim that glucagon-like peptide 1 (GLP-1) therapy represents a safe and effective intervention for improving glycemic control in critically ill, hospitalized patients with and without type 2 diabetes. They also criticize the recommendation to use insulin as treatment.
ACCESSION #
93918085

 

Related Articles

  • Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118-2125. BJERRE KNUDSEN, LOTTE; BERG NYBORG, NIELS C.; BO SVENDSEN, CLAUS; VRANG, NIELS; MOSES, ALAN C. // Diabetes Care;Dec2013, Vol. 36 Issue 12, pe213 

    A letter to the editor is presented in response to the article "A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe?" published in the journal in 2013.

  • Response to Comment on: Butler et al. A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe? Diabetes Care 2013;36:2118-2125. GALE, EDWIN A. M. // Diabetes Care;Dec2013, Vol. 36 Issue 12, pe214 

    A response from the author of the article "A Critical Analysis of the Clinical Use of Incretin-Based Therapies: Are the GLP-1 Therapies Safe?" published in the journal in 2013 is presented.

  • Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues. Hyun-Ji Chun; Hyuk-Sang Kwon // Journal of Korean Diabetes;2013, Vol. 14 Issue 3, p125 

    Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an...

  • Understanding incretins. Deane, Adam; Jeppesen, Palle // Intensive Care Medicine;Nov2014, Vol. 40 Issue 11, p1751 

    The article highlights a study on incretins. Topics discussed include the link of incretin effect with glucose ingestion resulting to an increase in plasma insulin concentrations, clinical relevance of using incretin hormones, insulinotropic effects of glucose-dependent insulinotropic peptide,...

  • Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes? Deane, Adam M.; Horowitz, Michael // Diabetes Care;Feb2014, Vol. 37 Issue 2, pe40 

    The authors comment on narratives relating to the use of incretin-based therapy for hospitalized patients with hyperglycemia. They describe the results of their mechanistic studies that evaluated incretin-based therapies in the critically ill. They also emphasize the use of insulin in...

  • Incretin hormones and the satiation signal. Holst, J J // International Journal of Obesity;Sep2013, Vol. 37 Issue 9, p1161 

    Recent research has indicated that appetite-regulating hormones from the gut may have therapeutic potential. The incretin hormone, glucagon-like peptide-1 (GLP-1), appears to be involved in both peripheral and central pathways mediating satiation. Several studies have also indicated that GLP-1...

  • Integrating Incretin-Based Therapy into Type 2 Diabetes Management. Brunton, Stephen A. // Journal of Family Practice;Jun2013 Supplement 1, pS1 

    The article discusses integration of incretin-based treatment in the management of type 2 diabetes which focuses on strategies to enhance self-management of the patient with the glucagon-like peptide-1 receptor (GLP-1R) agonists. It offers an overview of GLP-1R agonists and the dipeptidyl...

  • Obesity and diabetes: Two-for-one strike at incretins. Harrison, Charlotte // Nature Reviews Drug Discovery;Jan2014, Vol. 13 Issue 1, p18 

    The article discusses the research study published in the journal "Science Translational Medicine," which shows that investigational diabetes drug targeting two members of the incretin family of hormone receptors have greater metabolic effects that the approved drugs for diabetes. It says that...

  • Beyond Glucocentric ity: Nonglycemic Effects of Incretin-Based Therapy.  // OB/GYN Clinical Alert;Jul2012 Clinical Briefs in Primary, p14 

    The article provides information on the use of incretin class agents for cardiovascular outcomes as it is comprised of Glucagon-like peptide-1 (GLP-1) agonist Dipeptidyl peptidase-4 (DPP4) inhibitors

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics